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The graphene family has captured the interest and the imagination of an increasing number of scientists
working in diﬀerent fields, ranging from composites to flexible electronics. In the area of biomedical
applications, graphene is especially involved in drug delivery, biosensing and tissue engineering, with
strong contributions to the whole nanomedicine area. Besides the interesting results obtained so far and
the evident success, there are still many problems to solve, on the way to the manufacturing of
biomedical devices, including the lack of standardization in the production of the graphene family
members. Control of lateral size, aggregation state (single vs. few layers) and oxidation state (unmodified
graphene vs. oxidized graphenes) is essential for the translation of this material into clinical assays. In this
Tutorial Review we critically describe the latest developments of the graphene family materials into the
biomedical field. We analyze graphene-based devices starting from graphene synthetic strategies,
functionalization and processibility protocols up to the final in vitro and in vivo applications. We also
address the toxicological impact and the limitations in translating graphene materials into advanced
clinical tools. Finally, new trends and guidelines for future developments are presented.
Key learning points
(1) Superior performances of the graphene family materials over current biomedical tools
(2) Advantages, limitations and challenges of graphene-based materials for drug delivery
(3) General approaches and advances for constructing graphene-based biosensors and sensing implants
(4) Application of graphene in 3D scaﬀolds for tissue engineering
(5) Future perspectives and guidelines for a proper translation of graphene in biomedicine
1. Introduction
The increasing demand for more eﬀective, specific and safer
treatments in the biomedical domain is expanding the horizons
of the research towards more innovative therapies. In this
context, commercially available biomedical technologies are far
from being satisfactory, because they are limited by the intrinsic
properties of the materials employed. For instance, metal and
silicon are among the most used materials for the fabrication of
aﬀordable and conventional implant devices. However, their
poor long-term stability in physiological environments, rigid
mechanical properties and high inflammatory potential, may
result in strong limitations. Therefore, even when a material is
considered safe, control studies in the physiological conditions
should be performed to make sure the final therapy is eﬀective
and nontoxic.
Among the more promising materials under current careful
scrutiny, graphene has generated an increasing interest in many
areas of research, including electronics, composites, energy and
photonics.1 Graphene has also generated great expectations in the
biomedical field, due to its extraordinary mechanical properties,
accompanied by biocompatibility, transparency and electrical
conductivity. More specifically, graphene oﬀers simultaneously
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mechanical compatibility, cell adhesion and low toxicity prop-
erties, for applications in scaﬀold production, sensing and drug
delivery.
A large amount of research on graphene focuses on medical
applications, as there are specific properties that make gra-
phene a strong candidate for replacing current devices, in
particular its mechanical and electronic capabilities.2 Specifi-
cally, graphene’s Young’s modulus ranges between B20–40 GPa,
while the tensile strength lies between B15–520 MPa for
graphene cast into films,3 which places graphene amongst the
strongest materials. This set of properties, coupled to a high
flexibility, makes graphene the ideal component for flexible
biomedical electronic devices or implants, acting as a structural
reinforcement or as an integral element,4 since it is able to
accommodate on the surrounding biological tissue without
experiencing stress or fatigue. In addition, graphene possesses
broadband absorption and high transparency in the visible
range (B2.3% absorption for single-layer graphene),4 which
grants a unique role in medicine enabling optoelectronic
stimulation. The electronic properties of graphene are very
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important for medical purposes (e.g. 2 104 cm2 V1 s1 carrier
mobility and 1013 cm2 carrier density for mechanically exfoliated
graphene), in particular to act as conducting component, electrode
or support in bioelectronic devices,4 exceedingly outperforming
current silicon and noble metal analogues. Biocompatibility is
another important issue to take into consideration, since graphene
sp2 carbon surface allows strong, non-destructive, interfacial
interactions at a cellular level, which can be even improved by
chemical functionalization.3,4 As a matter of fact, the tunable
surface chemistry opens up many additional possibilities to
obtain useful functional derivatives of graphene.2 Accordingly,
a controlled chemical modification allows a precise control over
the drug quantity and the release rate in specific parts of the
body in drug delivery systems.5 The traditional materials for
bone tissue engineering, based on metals (titanium, stainless
steel, Co/Cr alloys) coated with polymers (e.g. ultra-high-
molecular-weight polyethylene) or ceramics (e.g. hydroxyapatite),
display long-term compatibility and durability issues.6 In the last
years, many reinforcements and coatings made of graphene-
based materials, applied to traditional implants, have shown
promising results in terms of mechanical properties and bio-
compatibility. Neural and bone tissue engineering is a current
huge medical business.3 Many materials are used to replace
nerve grafts and bones, acting as cell promoters: small inter-
ference RNA, silicone elastomer scaffolds, natural proteins (e.g.
collagen, fibronectin, keratin), polysaccharides (e.g. hyaluronan,
chitosan, alginate), and more recently biodegradable synthetic
polymers, including polyesters, polyurethanes or electroactive
polymers (e.g. polyaniline, polypyrrole). However, graphene, in
combination with many of these materials, has the ability to
dramatically improve their long-term lifetime, playing a crucial
role in cellular growth and activity enhancement. Moreover, the
versatile and tunable surface chemistry allows the attachment of
cellular growth factors. Graphene also contributes to important
advantages in biosensing. Graphene derivatives are able to
improve the functionality of conventional electronic components
like silicon-based semiconductors or metal electrodes in sensing
devices.4 The functionalization possibility and the electrical
properties of graphene are able to improve the sensitivity and
the range of analysis of the (bio)sensors. In addition, they can
overcome the main limitations of conventional materials in
sensing implants, such as the poor flexibility, the stability under
the harsh biological environment and the weak mechanical
strength.
A problem that is becoming more and more common in the
biomedical field is that, very often, a material generically called
graphene is employed. However, the broad family of graphene
products includes, among others graphene oxide, reduced
graphene oxide or graphene nanoplatelets.7 Besides having a
diﬀerent structure, these compounds possess very diverse
properties and may give completely diﬀerent biological
responses. In addition, these graphene products, in turn, are
not homogeneous species, but, rather, are represented by a very
broad group of substances with diﬀerent lateral sizes, oxidation
state and a varied number of layers. The lack of standardized
ways of reporting the characterization of graphene materials
and the absence of agreement on the necessary information to
report the detailed conditions used in a biological experiment,
make it sometimes diﬃcult even the reproduction of a pub-
lished experiment.8
Furthermore, there is plenty of published work, in which terms
such as biomedical graphene or biological graphene are used.
These definitions can create some confusion, especially because
they give the erroneous perception of safety, when using graphene
related materials, without having really proven their absence of
toxicity. However, this is still a challenging problem, even when
talking about biological grade definitions for chemicals in general.
Every company designs its own quality degree, including, some-
times, in the finest quality products, detailed specifications such
as: (a) the purity degree, (b) presence or absence of trace metals, or
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(c) some application tests. On the other hand, there is not a
common agreement on what is a medical grade material. For
instance, the USA Food and Drug Administration suggests
several materials research standards, in which not only the
physicochemical characterization of the material is included,
but also important information about the biological experiments
related to the same material, defining, in this way, a specific
grade of the material.9
Following these considerations, when preparing graphene-
based materials for biomedical applications, particular attention
should be paid to the characterization that will define the new
products. It should therefore be necessary to establish a common
background for the development of a master file for the bio-
compatibility evaluation of not only graphene itself but also the
graphene-derived materials. Physicochemical parameters should
be considered, pointing out the most useful characterization
techniques in each case. The adoption of this kind of standar-
dized data format, when reporting, could help to better compare
the diﬀerent graphene materials in order to clearly identify the
relationships between structures and properties, favoring the
development of predictive models and expanding our knowledge
about the relation between bio- and nanoworld, clearing the way
for clinical trials.
In this tutorial review, we will discuss the general principles
that have led to the consideration of graphene materials as
promising building blocks in biomedicine, with particular
emphasis on the experimental procedures that make biocompatible
this potentially unsafe material. In this context, we will focus on
drug delivery, sensing and tissue engineering of graphene-based
technologies.
2. Synthetic considerations
2.1. Preparation of CVD graphene, graphene oxide and
reduced graphene oxide
Depending on the medical application under consideration,
graphene derivatives can be produced by bottom-up or top-down
approaches. Generally, for the purpose of sensing, bottom-up
approaches are preferred, in particular chemical vapor deposi-
tion (CVD) is the technique of choice. This procedure, which is
considered inexpensive, produces high-quality monolayer and
few-layer graphene with a low number of defects, being signifi-
cantly useful for the production of bioelectronic devices. CVD is
carried out on poly- and monocrystalline metals, particularly
copper or nickel surfaces. In addition, when these substrates are
unsuitable for the final use, transfer methods of graphene onto
appropriate surfaces can be performed.2 A further promising
approach is the synthesis of graphene nanoribbons based on the
polymerization of polyaromatic monomers on surfaces.10 This
chemical synthesis oﬀers an atomic control of the structure and
the dimensions of graphene nanoribbons, leading to materials
with well-defined physical properties. Graphene on surfaces can
also be produced by chemical or physical exfoliation of bulk
graphite, followed by deposition on the substrate of interest.
These latter methods are cost-eﬀective, versatile, high-yield, and
allow large-scale productions. However, the morphology and the
dimensions of the obtained graphene are not very uniform.
Therefore, this route is not appropriate for producing
graphene-based electronic devices for biomedical applications,
because of the poor quality of the resulting electronic properties.
Rather, they can be used for applications in drug delivery or
tissue engineering where large amounts of graphene materials
are required.
On the other hand, exfoliated graphene sheets are highly
hydrophobic and tend to aggregate, exhibiting a low water dispers-
ibility. To obtain dispersions of graphene in water, interesting
strategies have been devised (vide infra). Recently, two other mem-
bers of the graphene family have become popular: graphene oxide
(GO) and reduced graphene oxide (rGO) (Fig. 1).1,2
GO represents the ‘‘hydrophilic derivative’’ of graphene. It
can be easily synthesized by the Hummers’ method and,
compared to graphene, oﬀers a richer surface chemistry due
to the presence of the oxygenated groups. Structurally, GO can
be considered as a single-layer graphene sheet, where the
amount of C atoms has dropped to 40–60%, in favor of a
higher presence of oxygen atoms. The sp3/sp2 ratio and the
nature of the organic groups is strongly affected by the source
of the graphite used, as well as by the synthetic protocols
adopted during the GO preparation. This variability strongly
influences the chemical reactivity and the macroscopic proper-
ties (dispersibility, refractive index, etc.). As already mentioned
above, there is not a single and exact GO structure. The study of
the morphological characteristics (by atomic force microscopy –
AFM, scanning and transmission electron microscopy – TEM
and SEM, and scanning transmission electron microscopy –
STEM) and the structural characterization (by Raman, Fourier
transform infrared spectroscopy – FTIR, solid-state nuclear
magnetic resonance – NMR and X-ray photoelectron spectro-
scopy – XPS), give a reasonable idea of the GO structure.
Fig. 1 Molecular structures of graphene, GO and rGO.
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In spite of the many advantages of GO, e.g., its remarkable
hydrophilicity, this nanomaterial is structurally defective, elec-
trically insulating and mechanically poorer than graphene.3 To
improve its properties, the chemical or thermal reduction of GO
(in order to remove oxygen functional groups and regenerate
the sp2 network) has beenwidely studied, providing rGO. rGO can be
considered as an intermediate structure between the ideal graphene
sheet and the highly-oxidized GO, thusmaintaining some and losing
some other properties of both materials. Morphological (AFM, TEM)
and functional (Raman, XPS, solid-state NMR) studies have
assessed rGO as a single layer graphene sheet that still retains
some functional groups after the reduction. Accordingly, the
structural restoration of the graphene features is never complete,
so that the final nanostructure does not quite match the ideal
graphene structure.
For all these reasons, additional preparation routes, providing
water-dispersible and non-defective graphene in appreciable
amounts are necessary and currently thoroughly investigated.
2.2. Preparation of graphene aqueous dispersions
The application of graphene materials in nanomedicine is
strongly conditioned by the need to handle and control the
behavior of these nanostructures in physiological conditions,
essentially complex aqueousmedia. While the water stabilization of
graphene materials based on GO and rGO may be relatively easily
achieved through mild stirring, shaking and/or sonication, the
much higher hydrophobicity of graphene makes it necessary the
use of external agents to induce the exfoliation and the stabilization
of the sheets. The methodology is based on the simple principle of
overcoming the van der Waals forces among the graphite sheets by
applying counterforces either perpendicular (normal) or parallel
(shear) to the graphitic crystalline planes. The mechanical exfolia-
tion of graphite11 with molecular (e.g. pyrenesulfonic acid), macro-
molecular (proteins, polymers), or supramolecular (micelles,
liposomes) surfactants has led to the eﬃcient separation and
stabilization of graphene sheets in water.12 A general scheme
of graphite exfoliation is reported in Fig. 2. However, the excess
of exfoliating agents may interact at a cellular level, often
complicating the understanding of the role of graphene in the
biological environment. Besides, many surfactants may cause
toxicity problems, such as hemolysis. Proteins such as bovine
serum albumin (BSA), used to exfoliate graphite down to few-
layer graphene, can be considered as biocompatible, but this is
not clearly the case for pyrene or other polyaromatic hydro-
carbon (PAH) derivatives.13 Therefore, after having obtained the
aqueous dispersion, it is necessary to remove the dispersants as
much as possible, leaving the minimum quantity indispensable
tomaintain the stability of graphene in suspension, its exfoliated
state and its structural integrity, ensuring not to jeopardize its
true potential in nanomedicine.
Ball milling is an exfoliation process ruled by shear forces in
which it is possible to control the applied energy to favor shear
or collision forces.11 By using a planetary mill, a high applied
energy may be useful for the exfoliation process, controllable
through the rotation speed and the possibility to work under
wet or dry conditions.11 For instance, the successful preparation
of few-layer graphene (FLG) in polar solvents, including water,
can be achieved by using 2,4,6-triaminotriazine (melamine) as
an intercalating agent in a planetary ball mill. This approach has
been further implemented by adding dialysis steps in hot water,
in order to remove the excess of melamine.14 These aqueous
suspensions can be freeze-dried, resulting in a soft powder made
of FLG, which can be easily re-suspended in aqueous media,
including culture media, at the desired concentration, without
compromising its structure.
There are a few other examples that aﬀord liquid-phase
stabilization of graphene in aqueous environments, without
the use of additives. However, for the moment, these methods
have not been explored in biomedical applications yet. This
could be ascribed to their early stage of development, or to their
Fig. 2 Schematic overview of the process for obtaining non-oxidized graphene in aqueous media by physical exfoliation of graphite.
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low production yields, or the requirement of very strict synthetic
conditions (controlled atmosphere, temperatures, etc.). An example
of this approach has been recently reported by Bepete et al.15 In this
work, graphene monolayers were obtained in water starting from a
potassium-graphite intercalation compound (KC8), followed by
exfoliation in tetrahydrofuran, eventually exchanging the organic
solvent for degassed water.15
However, the implementation of graphene materials as
advanced tools in biomedicine can be further improved and
becomes more versatile after surface functionalization. In the
last decade graphene have been successfully functionalized via
non-covalent interactions16 using amphiphilic units and polymers
or via covalent functionalization. In the latter case, typical reactions
include cycloadditions, radical and nucleophilic/electrophilic
additions.1 The properties of the final compounds strongly depend
on the synthetic route and on the post-functionalization strategy
adopted, in order to be tailored for the defined application.16
3. Biomedical applications of the
various graphene forms
3.1. Graphene materials as platforms for drug delivery
In principle, due to its high surface area, biocompatibility and
versatile chemistry, graphene materials can be used as carriers for
drug delivery.1,3 There is an increasing demand for the preparation
of multifunctional and versatile platforms, i.e., multidrugs or
theranostics (therapy and diagnostics). An extraordinary result
was reported recently, showing that FLG dispersions have a specific
killing action on monocytes, displaying neither toxic nor activation
eﬀects on the other immunocompetent cells. This therapeutic
activity of graphene was applied against an aggressive form of
cancer, namely the myelomonocytic leukemia, where the mono-
cytes are in a malignant form. In this work it was demonstrated
that FLG has the unique ability to cause specifically the
necrosis of monocytic cancer cells. Moreover, the comparison
between FLG and a common chemotherapeutic drug, etoposide,
confirmed the higher specificity and toxicity of FLG. Since
current chemotherapy treatments of leukemia still cause serious
side eﬀects, these findings may open the way to new and safer
therapeutic approaches.17
Graphene oxide and reduced graphene oxide can be more
easily handled, especially in aqueous media, since they generally
exhibit good water dispersibility and a very rich surface chemistry,
which allows the development of a wide range of biomedical
applications. Fig. 3 shows a scheme of GO- and rGO-based drug
delivery applications.
In the following sections, the strategies and the GO and rGO
uses in the drug delivery field will be presented and discussed.
3.1.1. GO-based carriers. GO has been extensively studied
as drug delivery carrier, but, in order to achieve reproducibility,
it is always necessary to pay attention to the GO preparation
procedures and on the graphite sources used. After performing
the classical Hummers or a modified Hummers’ method, the
reaction product is composed by single-layer and few-layer GO,
undesired graphite oxide and pristine graphite that must be
separated.18 In principle, to collect high quality material, the
GO fractions should be separated on the basis of their lateral
dimensions, since the delivery performances, i.e., loading abilities,
adsorption/desorption kinetics, and toxicity strongly depend on
their size.19
Structurally, the main diﬀerence between graphene and GO
is the presence of oxygenated groups on the surface of the
latter, which results in a better solubility in aqueous media, an
Fig. 3 Cartoon illustrating the applications of GO and rGO in drug delivery.
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easier handling and a richer surface chemistry.1,20 Each GO
sheet is roughly composed of two diﬀerent domains: one
hydrophobic region composed by sp2 carbon and another
hydrophilic zone, where oxygenated groups are present. There-
fore, the typical reactivity of GO combines the ‘‘classical’’ sp2 C
chemistry of graphene (1,3-dipolar additions, radical reactions,
Diels–Alder reactions, etc.) with the chemistry of the oxygenated
functions. Some of these reactions can be performed under
mild conditions and are suitable for sensitive biological moieties,
such as proteins or genetic material. However, we must keep in
mind that many biomolecules adsorb strongly on GO,16 thus it is
difficult to distinguish between adsorbed and covalently attached
products. The general rationale for multi-functionalization is to
use both covalent and non-covalent chemistry. In this case,
dispersants or targeting molecules are attached via covalent bond
to GO while drug molecules, generally lipophilic, interact with the
sheets via p–p stacking or other low polar interactions. The
covalent/non-covalent strategy is simple and versatile. In addition,
there is often a positive synergistic effect on the drug uptake/
release. Moreover, functionalization can increase GO dispersibility
in water or in the cell culture media, decreasing its cell/tissue
toxicity and inducing accumulation to target cells and tissues. For
example, biocompatible polymers (chitosan, polyethylenimine,
polyethylene glycol, etc.) have been widely tested. Among the
non-covalent approach, doxorubicin is one of the most selected
drugs to carry on. Those platforms have been successfully tested
for cancer treatments in vitro. Moreover, GO is characterized by
the presence of many organic groups on its surface, so that, when
planning a reaction with a specific GO functional group, it is
necessary to take into account that parallel or undesired reactions
may occur, which can drive to false interpretations. For these
reasons, control reactions should always be carried out in parallel.
As an example, we described an interesting case study related to
the carboxylic groups in GO coupling with amino groups, which,
for its versatility, is the most performed functionalization with
biomolecules in the literature.21 By comparing the products and
by different control experiments, we demonstrated that amino
functionalization takes place at the epoxide functionality rather
than at carboxylates.
The in vivo eﬃcacy of GO platforms is based on passive
targeting and, in particular, on enhanced permeability and
retention eﬀects, common to several cancer tissues, due to
hypervascularization. Unfortunately, passive targeting treat-
ments do not always show encouraging results when the
therapy is translated from in vitro to in vivo. Indeed, the
in vivo treatment is more complex and the therapy can lose
part of its eﬃcacy. In addition, side eﬀects due to unfavorable
drug release can negatively alter the whole cure. For these
reasons, active targeting therapies are generally preferred,
where targeting moieties, such as antibodies, peptides or others
are introduced on the GO surface (Fig. 3). Active targeting of GO
constructs favors the accumulation of the nanomaterial in the
desired tissues, enhancing its therapeutic results while decreasing
the side eﬀects.1,20 In addition, to follow the fate of the nano-
material in the body imaging molecules can be attached to the GO
surface. For this purpose, GO can be easily functionalized with
organic dyes, luminescent particles or radioactive compounds.
However, attention should be paid during these synthetic
strategies: GO, as all graphene family members, is an eﬃcient
luminescent quencher. This feature may compromise the
detection of the complex, so that non-luminescent imaging
molecules, such as magnetic probes22 should be favored. The
quenching property of GO can be used for feedback imaging, an
approach where the luminescence signal can be detected after
physical detachment of the dye from GO. This process, well-
established for the luminescence-based graphene sensors,23 can
be also applied to the preparation of sophisticated theranostic
tools. For instance, an in situ feedback imaging system based on
GO to detect in vivo apoptosis of cancer cells was recently
proposed.24 For this purpose, GO was functionalized with camp-
tothecin (the drug), folic acid (the targeting agent) and a fluo-
rescently tagged peptide corresponding to a native substrate for
caspase-3, an enzyme activated in apoptotic mechanism. Folic
acid active targeting allowed the accumulation of the function-
alized GO into the tumor tissues, where camptothecin is released,
caspase-3 is activated, cleaving the tagged peptide from GO and
inducing an enhanced fluorescence signal during the following
72 hours. This strategy provides a convenient and reliable
method for in situ and real-time monitoring of the therapeutic
response in animal models.
Drug release can also be tuned or stimulated by the intra-
cellular environment. Generally, drug release in a cell is due to the
change of the environmental conditions between the extracellular
matrix and the cytoplasm. Therefore, drug desorption from GO
can be activated by lowering the pH: this has been proven for
example for doxorubicin that undergoes the protonation of the
amino group of the sugar moiety leading to the destabilization of
the interactions with the GO sheet. The acidic drug desorption is
the prominent releasing process when the GO enters via endo-
cytosis into the cells, where it is digested into lysosomes that have
an acidic pH. However, the releasing process from GO could be
incomplete or even too slow causing an ineﬃcient eﬀect of the
whole therapy. The latest implementation in GO-based drug
delivery platforms relates to the use of stimulated drug release,
trigged by some external stimuli. The stimulated release is able to
increase the eﬀective drug dosage, leading to better therapeutic
performances. Moreover, the stimulus is applied locally on the
target cells, sensibly decreasing side eﬀects on healthy tissues.
Stimulated drug release is generally turned on by the photo-
thermal eﬀect.25 In fact, graphene absorbs light in the near
infrared region (NIR) and converts it into heat. The thermal
increase, produced inside targeted cells, activates the drug
release mechanism. More importantly, heat induces cell ablation
combining the advantages of chemo- with photothermal
therapy.25 Despite the recent implementation, photothermal
chemotherapies are far from being satisfactory. Several safety
issues have been raised, due to the local heating, such that
oxygenation, blood flow rate, or pH variation need to be fully
understood. In addition, especially in solid tumors, the GO
delivery is still not suﬃciently selective.
3.1.2. rGO-based carriers. Analogously to GO, rGO pos-
sesses some properties that may make it a promising carrier
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for biomedical applications. The reduction process removes
most of the oxygenated groups leading to a less polar surface,
thus enhancing its adsorption properties for less polar drugs.
In addition, compared to GO, rGO has an increased number of
sp2 carbon, therefore exhibits a higher absorbance in the NIR,
becoming an interesting candidate for classical photothermal
or chemo-photothermal therapies.26 However, the synthetic
procedures adopted strongly aﬀect the rGO structure and
properties, such as the nature of the organic groups retained,
its water dispersibility and its biocompatibility. The starting GO
material should be first considered, in particular the lateral size
and the C/O ratio. The most common reduction of GO is
performed using hydrazine, followed by aliphatic amines and
several other protocols.27 Usually, each rGO reduction may lead
to the retention of the desired organic groups. For instance,
hydrazine, hydroxylamine and sulfides are able to reduce epoxy
groups to alkene, while with alkylamines the reduction product
is stopped at the alcohol formation. Stronger reductants such
as Zn are able to reduce also the carboxylic acids at the edges.27
The procedure should be selected according to the organic
groups required.
As for GO, the combination of the covalent/non-covalent
strategy is still the most exploited, allowing the grafting of
dispersants, drugs, and targeting molecules. The most explored
preparation strategies for an rGO platform are the post-reduction
strategy and the in situ reduction/functionalization. The post-
reduction approach is the most used for rGO functionalization.
In this case, rGO is functionalized with target molecules after the
‘‘classical reduction’’ with hydrazine or ammonia. Dispersant
molecules and hydrophilic drugs are usually complexed via non-
covalent interaction. However, rGO prepared in this way may
induce a certain degree of cytotoxicity. This side eﬀect is mainly
attributed to the reduction protocol used and in particular to
residual hydrazine or ammonia. The presence of these hydro-
philic chemicals can improve the rGO dispersibility in cell
culture media, but enhances the toxicity of rGO, thus limiting
its application in the biomedical field. To solve these problems,
alternative strategies have been pursued to reduce GO. Several
studies describe the preparation of rGO using vitamin C, vegetal
extracts, peptides, and many more.27 rGO obtained following
these ‘‘green’’ protocols exhibits higher biocompatibility.
3.2. Graphene on surface
3.2.1. Graphene-based bioanalytical devices. In the last
decade, much eﬀort has been devoted to the development of
high performance biosensing devices, using advanced 2D
materials, in particular, graphene derivatives. In general, in
these biomedical devices, such as bioanalytical sensors as well as
sensing implants, graphene derivatives are usually supported on
surfaces.
Biosensors are commonly composed of two diﬀerent
elements: a receptor and a transducer (Fig. 4). A receptor is
the recognition element usually being a bioactive molecule with
specific interaction with the target. The transducer is respon-
sible for converting the chemical information from the recogni-
tion event into a measurable signal. However, the receptor is
omitted in diverse biosensors, since the direct interaction of
the analyte with the transducer produces measurable changes
of its properties. Graphene and its related materials can used as
the transducing platform in biosensing.4,28 Thus, chemical
modification of graphene materials is a mandatory step in
the production of biosensors for the attachment of the recogni-
tion elements when needed. For this purpose, covalent and
non-covalent strategies have been developed, which include
Fig. 4 General scheme of graphene-based biosensors (G, graphene).
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amide bonds with carboxylic groups of oxidized graphene
materials, the use of nanoparticles, p–p interactions, and the
immobilization in biomatrices.16,29 The distinctive properties
of the graphene family namely zero band-gap semiconductor,
high carrier mobility, quantum hall effect, high light transmittance,
and large active surface areas for binding biomolecules, make them
hot candidates for components on the surface of electrodes and
field effect transistors (FETs) in electrochemical, FET and optical
biosensors and for monitoring devices.
Electrochemical biosensors work by direct electron transfer
between the sensing platform and the electroactive species,
which can be the target molecule itself for the recognition
bioelement. The modification of the traditional carbon-based
electrodes for electrochemical measurements, e.g. glassy-
carbon electrode (GCE), with graphene derivatives oﬀers many
advantages due to their structural and electrochemical proper-
ties: they allow an increment of the signal-to-noise ratio due to
the high surface-to-volume ratio with good electron transfer
characteristics, a large electrochemical potential window, high
mobility and conductivity, multiple detections because of the
attachment of diﬀerent recognition elements and the possibility
of miniaturization of sensing elements. Graphene-based FET
(GFET) biosensors generally operate in a solution-gated FET
configuration, due to their very stable performance, low working
voltage and high transconductance. The sensing mechanism is
produced by the change of the electronic properties of GFET
induced by the interactions with the target element.4 Besides,
another common biosensing approach in biomedical applica-
tions is the optical sensing, which is based on changes in the
optical properties of the corresponding sensing platform when
the recognition of the target molecule occurs.
In the following sections, the preparation of graphene-based
sensors for the detection of bioactive molecules will be described
with special attention to the role of graphene materials.
3.2.2. Ex situ bioanalytical sensing. In the case of disease
diagnosis, the precise detection of small molecules, macro-
molecules and cells by an ex situ performances is becoming
more and more crucial. The ex situ biosensors are defined as
non-invasive devices that work out of the biological entity and
need a previous extraction of the corresponding sample for the
analysis.
The detection of small molecules is very useful for clinical
diagnosis. Among all the small targets, glucose is especially
emphasized, since it is clinically important for diagnosis and
prevention of common chronic diseases, such as diabetes.
Glucose detection is usually based on the quantification of
H2O2 produced during the enzymatic oxidation of glucose by
glucose oxidase in the presence of O2. This subject coupled to
the use of graphene-based devices has been recently reviewed
in depth.28,30 In general, this quantification is performed by
electrochemical sensors. As mentioned above, graphene derivatives
are very useful for electrode modification due to their high surface
area and electron conductivity, leading to enhanced heterogeneous
electron transfer and consequently higher signal intensities. Many
examples have been reported in the literature on enzymatic sensors
composed by graphene-based electrodes, where glucose oxidase is
attached to the graphene surface.28 For instance, the modification
of a GCE with nanoparticle-functionalized rGO allows further
modification with glucose oxidase, yielding a biosensor with low
limit of detection (LOD, 76 mM) and high sensitivity retention. In
addition, rGO-modified GCE not only detects glucose when
functionalized with glucose oxidase, but can also be used for
other recognition elements due to the ability of graphene
materials to immobilize molecules. The use of a GO-covered
electrode for electrochemical sensing also allows monitoring
intracellular glucose.28 The GO surface on a borosilicate glass
capillary permitted to attach glucose oxidase through amide
bonds, exhibiting linear glucose-dependence with wide concen-
tration range (10–1000 mM).
However, enzymes as glucose oxidase lose activity with
changes in pH or temperature. For this reason, an increasing
interest is focused on the development of non-enzymatic sen-
sors for glucose detection. In general, the enzymeless glucose
sensing devices use metal and metal oxide nanoparticles,
loaded on the graphene materials, as components to catalyze
the reduction of glucose.3
Small molecules secreted from living cells, related to the cell
activity, can also be detected using graphene-based electrodes.3
In particular, the detection and quantification of dopamine and
related metabolic derivatives is crucial due to the role that they
play in several human diseases and neurological disorders.
Various graphene-based sensing methods have been developed
for the detection of this neurotransmitter and its metabolic
derivatives.28 In this regard, an rGO-based microelectrode array
was fabricated on a flexible platform by nanoimprint lithography
for detection of dopamine and H2O2.
4 This case proves the
advantage of using graphene derivatives, since they allow the
miniaturization of the device in an array of microelectrodes,
which do not alter the sensing properties. The graphene-based
array exhibits detection limits of 0.26 mM and 0.35 mM for
dopamine and H2O2, respectively.
One of the most relevant examples of graphene biosensors is
their use for the detection of nucleic acids.31,32 The interest for
such targets has increased exponentially in the past years,
because of their significance in gene or pathogen detection
and molecular diagnosis. Electrochemical sensors are the most
employed sensors for nucleic acid detection.29 Such detection is
generally based on the hybridization events where complementary
nucleic acids to the target are the recognition element. These
devices are very sensitive because the hybridization leads to
changes in the electrochemical signal enabled by the easy
functionalization of graphene materials with nucleic acids by
covalent and non-covalent approaches. This functionalization
capability yields to a close interaction between the graphene
material and the recognition element, leading to an improved
electron transfer. For instance, rGO covalently linked to amino-
single-stranded DNA, as the recognition motif on its carboxylic
groups, aﬀorded an impedimetric sensor for the detection of
amelogenin gene, related to dental diseases. The sensing device
showed a wide detection range with a LOD of 3.2  1015 mM
and a high specificity as compared to non-complementary DNA
strands.
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As above-mentioned, the most employed graphene materials
as transducing component are oxidized materials due to the
large defect degree, since heterogeneous electron transfer
occurs at defects and edges of the corresponding material.
However, their low conductivity is a disadvantage as electrode
component. By combining graphene materials on a surface, it is
possible to exceed the intrinsic limitations. As a representative
example, an electrochemical biosensor for the detection of human
immunodeficiency virus 1 (HIV1) gene was assembled, based on an
double layer electrode composed by rGO on a graphene electrode.29
This sensing device achieved, for the detection of the HIV1 gene, a
wide detection range (101–106 mM), a low LOD (1.58  107 mM)
and selectivity in comparison to non-complementary DNA strands.
The combination of rGO and graphene in a double-layered
electrode showed a good electron transfer activity in comparison
to segregated graphene- and rGO-based electrodes. This behavior
was attributed to a combination of the large number of electro-
active sites in rGO and the highly conductive nature of non-
defective graphene.
Graphene is a promising material for fast gene sequencing.
The translocation of double-stranded DNA through graphene
nanopores was described by diﬀerent research groups, opening
the possibility of DNA sequencing using graphene devices, a
topic that has been recently reviewed.33 However, several lim-
itations were found, as for example the fast translocation (that
avoids achieving single-base resolution) or clogging eﬀects
between DNA and graphene material due to a strong hydro-
phobic interaction. In this regard, the available functionalizing
ability of graphene materials allows reducing the closure of
graphene nanopores with DNA by hydrophilic modification
with pyrene-ethylene glycol.4 Nevertheless, graphene-based
nanopore devices are at an early stage, and some of their
fundamental features must be still investigated. Indeed, other
2D materials and device architectures are being proposed, as for
example, monolayer dichalcogenides or single-stranded DNA
sequencing based on p–p interactions between nucleobases
and a nanoribbon deposited on a nanochannel (as demonstrated
theoretically).
Electrochemical sensors are also very popular for the detec-
tion of macromolecules such as proteins. Usually, these types of
sensors are based on immunoassays taking advantage of the
intrinsic sensitivity and specificity of the antibody/antigen inter-
action. Again, in these sensing systems, the advantage of using
graphene materials as transducing platforms was evidenced.28
Apart from the improved electron transfer properties in the
electrochemical measurements, multiple detections are possible
with rGO-modified electrodes. A clear example is the developed
electrochemical immunosensor that simultaneously detects two
diﬀerent antigens, the cancer carcinoembryonic marker and the
squamous cell carcinoma antigen. The sensor is based on a GCE
modified with covalently aminated rGO where the respective
antibodies were immobilized.28
Graphene-modified surfaces present a high ability to strongly
interact with bacteria and cells as well. Bacteria detection is generally
performed by FET or electrochemical sensors, both functionalized
with antimicrobial peptides on graphene platforms.3 Regarding cell
detection, the strong interaction between cells and graphene
surfaces allows the development of highly sensing and isolating
devices. Recently, a microfluidic chip based on an optical
graphene sensor allowed a leukemia single T-cell detection on
real-time, among abundant normal immune cells.3 The sensing
mechanism is based on changes of the refractive index when
cells are adsorbed on the graphene material. The resulting high
sensitivity of the optical sensing is explained in terms of parti-
cular optical properties of the ultra-thick rGO. Graphene sensors
are also develop to address the problem of detection of circulat-
ing cancer cells, which are the responsible for the cancer
metastases. For this kind of detection, there is an urgent need
for the development of highly sensitive sensors, due to the very
low concentrations of circulating tumor cells in real samples. An
illustrative example of graphene-modified surfaces in sensing is
a developed microfluidic device for detection and isolation of
diverse circulating tumor cells from blood samples of pancreatic,
breast, and lung cancer patients.16 The chip was composed by
non-covalently functionalized GO with an aminated phospholipid
derivative on flower-like gold patterns, where the corresponding
specific antibodies where chemically attached. The GO/Au device
showed an excellent sensitivity (3–5 cells per mL of blood) for the
tested circulating cancer cells and was even able to capture them
at low concentrations. The reported capture yields and detection
sensitivities were much higher than the ones reported in the
literature. It can be anticipated that this kind of graphene devices
are paving the way for next-generation flexible implants for the
in vivo analysis of cells and the identification of cancer cells.
3.2.3. In situ sensing implants. Sensing implants are emerging
as promising bioanalytical sensors in biomedical research because
they can perform real-time analysis and personalized diagnosis.
Unlike ex situ biosensors, sensing implants work in a continuous
and long-term analysis under mechanical stress in biological
environments. Due to these challenges, graphene-based materials
on surfaces are also gathering interest as components in body
implants. They are mechanically robust, flexible, and chemically
inert, with good biocompatibility, contributing to overcome the
major challenges for high-performance of in vivo sensing implants;
however, they are still at an early stage of development.
Biocompatibility is a particularly important subject for a
sensing device, because non-biocompatible devices can lead to
rejection from the user, as well as degradation of the implant.6
The modification of device surfaces with graphene materials can
enhance their biocompatibility. Especially, oxidized graphene
materials are favorable for biocompatible implants due to their
hydrophilicity. In addition, graphene functionalization can
modulate biocompatibility.
Another challenge for body implants is their miniaturization.
The use of graphene materials allows the reduction of electronic
components to the nanoscale. A representative example of this
advance on graphene sensing devices, together with good bio-
compatibility, is the recently reported wearable and wireless
nanobiosensor for bacteria detection in saliva.3 This sensing
device consisted of graphene-based electrodes and a printed
antenna onto a biocompatible silk thin-film substrate, which
allowed the adhesion on irregular tooth surface. The capture of
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bacteria by antimicrobial peptides on the graphene surface
resulted in a conductivity change of the graphene film, which
was wirelessly monitored by radio frequency. By assembling
antimicrobial peptides on CVD graphene, this wearable sensor
successfully detected around 100 Helicobacter pylori bacteria in
1 mL of human saliva. Therefore, the graphene device provided
sensitive and specific detection of bacteria on biosurfaces, which
can be used in diagnosis for continuously detecting bacterial
infection through a non-invasive modality.
The mechanical properties of graphene materials are also
fundamental for constructing body implants. This is clearly obvious
in another main application of graphene-modified surfaces, related
to the field of the cell and tissue monitoring by using FETs and
electrodes. Metal and silicon-based devices are widely used to
manufacture conventional implants. However, they have two sig-
nificant limitations: (i) no flexibility, and (ii) poor chemical stability
in the biological environment. Due to these factors, graphene-
modified electrodes and the above-mentioned GFETs exhibit a high
potential for recording the electrical activity of neuronal and cardiac
cells and tissues, because of the possibility of constructing flexible
electrodes, which is an important property for implants on soft
tissues, in addition to the mentioned strong interaction of graphene
with cells and their high biological stability.
For instance, the use of graphene derivatives allows to prepare
flexible electrodemicroprobes, which can record electrophysiological
signals for the very soft neuronal and cardiac tissues.3 There is a
representative example of the modified flexible microprobe with
CVD graphene, which could record electrocardiograms from the
heart of an animal. The graphene-based probe has shown a high
performance and good stability with no changes after use. Moreover,
the hydrophilic version of this graphene device presented a higher
level of sensitivity than the hydrophobic one, probably due to a
better biocompatibility.
In addition, several research groups have developedGFET devices
to study the electrical interaction with diverse cells, paving the way to
future sensing implants.3 For instance, arrays of solution-gated FET
composed by large areas of CVD graphene were used to record
signals from human embryonic kidney cells. Besides, they can also
quantify the release of ions by human embryonic kidney cells onto
graphene transistors, helping to understand the cell–transistor
coupling. More recently, GFET array on a flexible and biocompatible
substrate was used to monitor variations in the electrical membrane
potential of cardiac muscle cells with excellent signal-to-noise ratio
and with no degradation after repeated bending.34
Graphene derivatives can also provide extraordinary optical
properties, as high transparency, to sensing implants.4 For
instance, the combination of the broadband transparency,
good electronic conductivity and flexibility of CVD graphene
with a carbon-based electrode array resulted in an eﬃcient
multifunctional neural implant on a rat brain. This implantable
device could perform in vivo imaging under light stimulation,
together with recording neural signal.
3.3. Graphene scaﬀolds for biomedical applications
3.3.1. Three-dimensional structures of graphene materials.
The assembly of multidimensional structures using graphene-
based materials has allowed to enhance the optical, electrical
and mechanical properties of these nanostructures. These
functional constructs are typically classified according to the
dimensionality of the system, either one-dimensional (fibers,
yarns or ribbons), or two-dimensional (papers, films) or even
three-dimensional.3,35 In general, for many applications and in
particular in nanomedicine, the three-dimensional assemblies
are the most pursued as they can aﬀord more available surface
area and can also be tailored in terms of porosity, mechanical
properties and lightness. On the basis of these properties,
three-dimensional graphene assemblies have been considered
suitable scaﬀolds for medical purposes, either as a substrate for
the growth and diﬀerentiation of cells, or as implants to replace
tissues in living beings. Moreover, it is important to note that
these scaﬀolds may or may not be combined with soft polymers
or inorganic structures, giving rise to interesting nanocomposites.
The most common examples in nanomedicine deal with the
graphene–polymer combination, very extensively devoted to the
growth and development of neuronal cells or as functional
components in stimuli-responsive drug delivery.3,35 But there
are also numerous examples of graphene–inorganic combina-
tions, e.g., with hydroxyapatite, whose related scaffolds are
promising for human bone regeneration.36
In the next sections, we will discuss the approaches according
to the graphene content, resulting in: (i) nanocomposites with
graphene as the minor component; (ii) nanocomposites with
graphene as the major component; and (iii) only-graphene-based
scaﬀolds.
The scaﬀolds described so far in the literature mostly involve
gels, or cross-linked hydrogels (from which it is possible to
create aerogels after removing water by freeze-drying).35,37
Fig. 5 shows a general scheme of the most common trends in
three-dimensional graphene-based scaﬀolds. These morphologies
have shown truly unparalleled results and good biocompatibility,
oﬀering promising prospects in the biomedical field.
3.3.2. Nanocomposites with graphene as the minor com-
ponent. The synthesis of soft polymers by melt/solution mixing
or by in situ polymerization in the presence of small amounts of
graphene derivatives (typically in the range from 0.1 to 10 wt%)
is the most followed approach to attain a three-dimensional
nanocomposite scaﬀold.5
The role of the nanomaterial within the polymer network is
primarily intended for reinforcing the matrix (i.e., increasing the
stiﬀness and toughness), whose intrinsic mechanical properties are
often below the requirements for medical applications,35,37 in
particular when molecular loading is involved. Several examples
have been designed including the radical polymerization and
cross-linking of acrylic monomers to generate three-dimensional
reinforced hydrogel scaﬀolds, suitable for medical purposes, as
these are well-known for their biocompatibility and similarity to
soft tissues. The most representative examples of such cross-
linked hydrogels in medicine are poly(methacrylic acid), poly-
(acrylamide) or poly(N-isopropylacrylamide).35,37 Since the synthesis
of cross-linked hydrogels is usually carried out in aqueous environ-
ment, the achievement of graphene materials stably suspended in
water becomes a crucial task, if this nanomaterial is to be mixed
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with the matrix during the polymerization process. The graphene
content in the final nanocomposite is tailored by its concentration
in the polymerization medium, generally providing better
mechanical consistence and higher electrical and thermal con-
ductivities to the system than its blank counterpart. Additionally,
these nanostructures may also bring along unanticipated
features, such as a smart behavior based on improved respon-
siveness to external stimuli, enabling novel approaches in nano-
medicine, as is the case of on-demand drug delivery.3,5 An
illustrative case consists in the preparation of graphene/poly-
(methacrylic acid) nanocomposites by the in situ polymeriza-
tion strategy, with water-suspended graphene from the ball
milling technique (at concentrations from 0.05 to 0.2 mg mL1).38
These scaﬀolds showed an unprecedented ability to release
a drug upon pulsatile electrical stimulation, with an excellent
control on the delivery of the drug, keeping its structural
integrity, unlike the non-reinforced parent matrix. The positive
eﬀect of graphene was also evidenced in the in vivo perfor-
mances of these electroresponsive scaﬀolds, as the nanomaterial
can suppress the resistive heating eﬀects of the electrical pulses
and grant biocompatibility with minimum tissue damage.38
This example clearly shows how small amounts of graphene
are able to exert a prominent stimuli-response capability,
by improving the intrinsic eﬀect of the matrix, keeping its
structural shape and consistence, and eliminating unwanted
side eﬀects. This kind of three-dimensional scaﬀolds can be
envisioned for many types of therapeutic requirements, such as
those in chronic illnesses needing a precise and tailored dosage
pattern.38
It is worth noting that the combination of polymers with
small amounts of graphene is not the only way to achieve this
kind of three-dimensional architectures. Another commonly
employed method is the deposition of graphene derivatives
from a liquid suspension over a preformed scaﬀold, without
compromising its structure and porosity.3,35,36 This is the case
of many examples reported for collagen, hyaluronic acid or
hydroxyapatite scaﬀolds subjected to immersion or dip-coating
in GO or rGO suspensions.36 The native scaﬀolds have already
shown for years to have a proven osteogenic eﬀect, but their
mechanical and surface properties could be further improved,
so that these graphene-based coatings provide a step ahead.
These nanocomposite scaﬀolds have been tested both in vitro and
in vivo, exhibiting osteogenic diﬀerentiation of humanmesenchymal
stem cells (hMSC) in spontaneous and/or accelerated mode.36
Chemical modification of graphene-based nanostructures
can be also useful to link growth factors or other osteoinductive
biomolecules in order to finely tune cell diﬀerentiation.36
3.3.3. Three-dimensional scaﬀolds entirely based on graphene.
The natural self-assembly potential of graphene family nano-
structures has been widely explored to build up ‘‘all carbon’’
three-dimensional scaﬀolds, useful in nanomedicine. In this case,
either GO (and related structures) or pristine (non-oxidized)
graphene have been proposed. The former is extremely versatile
due to the abundant presence of oxygen functional groups in its
structure, which grants hydrophilicity and can form hydrogen
bonds with water. The control over the colloidal properties of GO
aqueous suspensions, balancing attractive vs. repulsive forces
(via, for example, the concentration, pH, ionic strength, etc.) can
Fig. 5 Graphene-based three-dimensional scaﬀolds for use in biomedicine.
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cause the spontaneous interconnection of GO sheets, hence the
gelation of the system.3,35 The usual procedures for synthesizing
pure GO/rGO scaﬀolds are based on hydrothermal treatments,
chemical precipitation (both leading to hydrogel structures),
or freeze-drying (which mainly generates aerogels or foams). In
a noticeable number of occasions these scaﬀolds have been
targeted for nanomedicine. To give a highlighting example,
Serrano and co-workers reported a GO-based scaﬀold by sub-
mitting a GO aqueous suspension to unidirectional freezing
in liquid nitrogen, at a controlled immersion rate, followed
by lyophilization.39 Flexible and porous three-dimensional
architectures were thus obtained, but still unsuitable for
medical applications as the GO hydrophilicity would cause
the degradation of the scaﬀold upon contact with aqueous
media. In order to solve this problem, the authors treated the
GO foams with hexamethylene diisocyanate vapors and sub-
jected them subsequently to a treatment at 200 1C to promote
the thermal reduction and cross-linking, ending up in an
architecture perfectly resistant to aqueous environments. These
novel chemically-modified scaﬀolds were used as substrates for
neuronal growth, exhibiting excellent cell viability and high
synaptic density (containing both neurons and glial cells rich in
dendrites and axons).39 This case proves that chemistry allows
to accurately control the morphology and the physical properties
of GO-based three-dimensional scaﬀolds, leading to highly con-
sistent and biocompatible porous materials. The versatility in
terms of texture, surface chemistry, possibility of functionalization
and controllable stiﬀness/toughness represents an enormous
potential for cell culture, in particular neuronal cells, with an
eye to nerve regeneration.
The case of pristine (non-oxidized) graphene three-dimensional
scaﬀolds represents a quite diﬀerent approach. One of the most
followed trends is to use a disposable template from which
building up the graphene scaﬀold, followed by the removal of the
template. Many research groups have used Ni foams as templates
since they are aﬀordable and also catalyze the subsequent growth
of graphene sheets by the CVD technique, mostly usingmethane as
the carbon source.35 The Ni template can be etched away with
strong acids (e.g., HCl, HNO3) yielding a graphene three-
dimensional porous scaﬀold, exhibiting high electrical conductivity
due to the lack of structural defects and the low contact resistance
at the sheet junctions.35
An application is represented by the recent use of Ni-
templated CVD-grown graphene scaﬀolds for the in vitro culture
of microglia and neuronal stem cells, where the medium
produced by microglia within those scaﬀolds could promote
the migration of stem cells.40 The relevance of these results
relies on the fact that graphene substrates with identical sur-
face chemistry but built in a two-dimensional fashion did not
show any of these eﬀects on neuronal stem cells,40 emphasizing
the critical role that the morphology, dimensionality, accessible
surface and porosity of the scaﬀold have on the eventual
medical application.
3.3.4. Polymer nanocomposites with graphene as the
major component. The fabrication of polymer nanocomposite
scaﬀolds is also possible starting from a pure graphene-based
foam, since this three-dimensional architecture can be subjected
to a polymer infiltration method (in the melt or in solution), or
an in situ polymerization step, to produce a nanocomposite with
a continuous and interconnected filler phase and with low
amount of polymer in comparison to graphene. The best known
example of this is the use of a poly(dimethylsiloxane) elastomer,
which can change its electrical resistance with bending, a
promising feature for electromechanical devices.35,37
Another interesting example is represented by a copolymer
made of poly(lactic acid) and poly-e-caprolactone, dip-coated
into a Ni-templated CVD-grown graphene foam. The resulting
nanocomposite, with a uniform coating of the polymer phase,
was used for in vitro hMSCs culture over a period of 28 days,
while the results were compared to a control scaﬀold based on
the pure (uncoated) graphene scaﬀold counterpart.41 Both
kinds of scaﬀolds succeeded in the survival and proliferation of
hMSCs, but, surprisingly, the uncoated graphene foam showed
abnormal cell growth behavior (with a deformed and highly
elongated shape) while in the polymer nanocomposite scaﬀold
hMSCs grew normally, keeping their original morphology.41
The authors ascribed these phenomena to the diﬀerences in
mechanical strength of the ‘‘graphene-only’’ scaﬀold vs. the
polymer coated one, since the polymer acts as a reinforcement
of the structure providing improved resistance in both com-
pression and tension modes, at the nanoscale level and in
macroscopic tests.
However, the classical approach of mixing dissolved/molten
polymers (or polymerizing in situ) with powdery graphene
materials has also been explored for three-dimensional poly-
mer nanocomposites with high content in graphene,37 and
those can be also applied as scaﬀolds for nanomedicine pur-
poses. By controlling the rheological properties of the blends
(i.e., through the polymer/graphene ratio, the solvent amount,
the mixing methodology, etc.), it is possible to design gels and
inks with unique processability. A particularly appealing
demonstration of this approach has been reported.42 In this
work, the authors fabricated a graphene ink by solution mixing
with a biocompatible polymer (polylactide-co-glycolide) with a
ratio of 75 : 25 wt% (graphene : polymer). This ink possesses the
ideal properties to be extruded through a 3D-printing device,
leading to three-dimensional honeycomb graphene scaﬀolds,
capable of reaching the centimeter scale in a relatively easy and
scalable manner. These scaﬀolds present enhanced electrical
conductivity, mechanical flexibility, and are also biodegrad-
able. These 3D-printed graphene scaﬀolds granted the viable
growth and proliferation of several cell types, including adult
hMSCs, which developed into neuron-like shapes. Additional
in vivo tests after subcutaneous administration in mice demon-
strated a good biocompatibility with no disintegration of the
scaﬀold or migration of graphene to the main organs. More
interestingly, these scaﬀolds have confirmed practical applica-
tion in neurosurgery, where the composite could be success-
fully cut and sutured to a nerve bundle in a simulated
chirurgical intervention to a human corpse, which provided
higher expectations towards a feasible medical application.
This example displays how the revolutionary application of
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cutting-edge processing techniques, such as 3D-printing, represents
a step forward in the building of graphene-based three-dimensional
scaﬀolds.
3.4. Considerations on the impact of graphenes in the
biomedical fields
Before the translation of graphene materials into clinical uses,
the assessment of their safety is of paramount importance.43
Most of recent work shows negligible toxic eﬀects of graphene
materials. For instance, in vitro tests on well-established cell
lines displayed a general good biocompatibility of graphenes.
Unfortunately, simple cytotoxicity tests do not satisfy the strict
screening criteria for translation of a new nanomaterials into
valuable clinical uses. The European Scientific Committee on
Emerging and Newly Identified Health Risks has recently
included graphene in the category of hazard substances.44
Indeed, some of the available results indicate that graphene
may cause adverse environmental and health eﬀects, although
we still have to fill in many gaps on risk-related knowledge.
Evaluating the toxicity of graphene is a rather diﬃcult task.
Compared with simple molecules, where the main toxicological
criteria to consider are concentration and exposure type and
time, nanomaterials require the evaluation of a higher number
of parameters including size, shape and agglomeration state.
In case of the graphene family nanomaterials, the safety
evaluation is even more complex, due to the fact that we have
to deal with materials that diﬀer also in atomic composition
(graphene, GO or rGO). For this reason, there is not a unique
answer to graphene toxicity but rather a more complex scenario.
There is still a limited amount of data in the literature on the
graphene impact on health. For the sake of clarity, in this
paragraph we will try to summarize the main safety parameters
that need to be addressed. First of all, the field of application
must be considered. Indeed, toxicological tests should take into
account the real conditions (i.e. inhalation vs. skin contact, low
vs. high dose exposures) by which graphene materials come into
contact with a living organism. This latter is necessary to under-
stand the risk-to-benefit balance of a graphene-based therapy.
Sensing applications require a relatively low quantity of gra-
phene that is generally present as a single-layer on an electrode
surface. In this case the assessment of the toxicity issues covers
the interaction of graphene devices with cells and tissues,
while longtime exposure must be investigated to avoid chronic
inflammations. Applications in drug delivery and tissue engineering
necessitate the use of higher quantities of material. Here, the
concentration issue is more relevant. In particular, an ideal
drug delivery system should guarantee an eﬃcient delivery
of the therapeutic molecules and a subsequent elimination/
degradation of the material from the body. For tissue engineering
instead, graphene materials integrated into a scaﬀold may remain
for long time in the body, so long-term toxicity studies are
necessary. In addition, the synthetic production methods must
be carefully scrutinized, as most of the discrepant results obtained
on toxicity tests can be attributed to an ineﬃcient purification
protocol.43 In most cases, the toxic response was not attributed to
the graphene material but to the contaminants present in the
sample.43 For instance, CVD graphene can be produced easily
without the presence of functional groups but toxic metal ions
may contaminate the film during the step of graphene transfer
from the support. Similarly, top down preparation strategies
require rigorous cleaning processes. Graphene exfoliation deals
with the use of amphiphilic molecules that, if not carefully
removed, may cause tissue inflammation. Modified Hummers’
methods used for the preparation of GO are based on the use of
manganese that may result highly toxic to cells if not completely
removed. For this reason, nowadays more and more graphene
material producers tailor their synthetic/purification protocols to
produce ‘‘biograde’’ graphene materials. As we have already
mentioned previously, this definition should be carefully con-
sidered since there is not a standard approved protocol that can
assess the graphene ‘‘biograde’’ yet. In addition there is no clear
knowledge of the nature of the possible contaminants (i.e. heavy
metals, residual graphite, endotoxins, etc.). Morphological
characteristics of the materials play also a fundamental role in
influencing the toxic eﬀects. For example, comparing GO to
carbon nanotubes, it was shown that they display diﬀerent
toxicity for neurons.45 This eﬀect was attributed mainly to the
diﬀerent shape of the two types of carbon nanomaterials.45 Size
and agglomeration of graphene materials must be also taken
into consideration. Indeed, the lateral size of graphene flakes
can span from few nanometer up to microns. In addition, non-
functionalized graphene tends to form strong multilayered
aggregates while GO and rGO are generally present in single-
or few-layers. About the impact of lateral size, in vivo studies
using diﬀerent graphene forms have highlighted that the lung is
the organ with the highest risk of damage.46 In this case, larger
flakes seem to be more toxic than smaller flakes.43 The accumu-
lation of graphene materials with large size (4100 nm) into
lungs resulted independent from the administration routes,
mainly leading to inflammatory responses.44 On the other hand,
a recent study demonstrated that intravenous administration of
radiolabelled GO flakes led to significant urinary excretion.47
Studies on biodistribution, accumulation and elimination of the
diﬀerent types of graphene are still scarce. The published work
mainly concerns GO and does not attempt to compare the eﬀects of
the diﬀerent characteristics of the nanomaterials, like lateral size,
oxygen content, number of layers. However, these preliminary data
on how graphene nanomaterials interact with the diﬀerent organs
are very important to assess their safety profile and eventually for
their development toward future biomedical applications. These
studies certainly need more eﬀort and should be also combined
with those proving in vivo biodegradability.
Among the structural characteristics of graphenes, it was
reported that size is relevant on the internalization mechanism
into the cells. Indeed, studies on macrophages pointed out that
the intracellular localization of GO was dictated by size, thus
leading to diﬀerent compartmentalizations.48 Also, bigger GO
flakes induced a much stronger inflammatory response with
high release of pro-inflammatory cytokines.43 Less investiga-
tions have been reported on the change of agglomeration state
(single-layer vs. flew-layer vs. multi-layer graphene). The oxida-
tion state and in general surface chemistry are additional
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parameters that need consideration. Graphene materials are
characterized by a large and complex surface area. The surface
is the most important part of the flakes. In fact, the various
interactions between the sheets and the small molecules, proteins
or cells, are mediated by surface interactions. Graphenes with low
polar surface showed a general low stability with a certain tendency
to agglomerate. In addition, an apolar surface strongly adsorb less
polar moieties such as hydrophobic proteins or other lipophilic
molecules present in the extracellular matrix.48 In particular, as for
many other nanoparticles, once in contact with biological fluids,
the hydrophobic surface of graphene can strongly adsorb proteins
forming a corona, which stabilizes the flakes in solution avoiding
precipitation. However adverse interactions also occur aﬀecting
biodistribution or cells interaction. In particular, in the case of
proteins of the complement system, acute inflammations may
occur.48 This behavior is typical for graphene and some rGO. On
the other hand, polar surface graphenes are characterized by a high
colloidal stability in diﬀerent aqueous media.48 Polar GO shows a
higher influence on hemolytic activity leading to a potential
thrombotoxicity.48 These results are in contrast with other studies
that report almost no hemolysis after GO injection.49 Interestingly,
it was shown that GO biodegradation can be modulated by
dispersibility.50 In this study is has been proven that GO can be
digested by peroxidases naturally present in cells. The bio-
degradation of graphene materials can avoid bioaccumulation
thus limiting its long-term toxicity. Moreover, studies from
diﬀerent groups incontrovertibly demonstrated that most of
the already mentioned clinical side eﬀects may be sensibly
reduced or avoided by surface functionalization.46,48,51 Sum-
marizing, graphene toxicity still needs a thorough evaluation.
The current data are still controversial. This is particularly due
to the variability and inhomogeneity to the graphene samples.
Most of the drawback of graphene-based therapy could be
alleviated by chemical surface manipulations. A standardiza-
tion of the graphene materials used is finally necessary to better
address and answer to all toxicological issues.
4. Conclusions and guidelines
The biomedical applications of graphene represent a field in
continuous expansion. Basic investigations demonstrate the
high potential of graphene and its derivatives in many impor-
tant applications, including drug delivery, tissue engineering
and sensing. However, the scarce synthetic control, the lack of
reproducibility and the diﬃcult characterization render these
materials weak candidates for real world applications. In fact,
nanomaterial-based devices for medical use require approval by
the regulatory authorities, often concerned with the potential
toxicity of the new materials. In relation to the toxicity of
nanomaterials, some authors have already described more than
ten key factors that should be considered to define its safety
grade.52 However, since the nanomaterial can change its nature
during the biological tests, its physicochemical characterization
should be carried out under similar experimental conditions,
thus making this task even more complex. For this reason, in
order to generate a standardized way of comparing characteriza-
tion and results, an agreement should be reached on which
crucial factors have to be considered.8 In this direction, there are
some recent eﬀorts by scientists working in nanoinformatics
focused on establishing the minimal information about nano-
material characterization.53 However as commented above,
standards may also include information concerning processing
of the material and the biological test already accomplished.
Regarding graphene materials, there are already some physico-
chemical factors considered essential in every characterization: the
oxygen content, the lateral size, and the number of layers.54
Nevertheless, there is still no clear conclusion on the diﬀerences
in biological behavior between large and small sheets, single-, few-
and multi-layer graphene samples, while the amount of oxygen
can also provoke undesired eﬀects. As stated earlier, achieving an
aqueous dispersion of graphene-based nanostructures is crucial to
advance in any targeted biomedical applications. GO conjugates
have an easier handling in aqueous media, while pristine (non-
oxidized) graphene requires the use of external chemical species to
obtain stable sheets in suspension. Regardless of their intrinsic
biocompatibility, in order to study the true role of graphene, these
dispersion agents should be perfectly quantified, trying to mini-
mize their possible biological eﬀects.
Some other relevant compositional features are often
ignored, such as the presence of trace of impurities, which,
sometimes, can be the sole responsible of the toxicity in a
graphene-based sample.55 Metals require special attention
since their toxic eﬀects may be more acute even in very tiny
amounts. Some graphene production methods include the use
of Ni templates or Mn species (Hummers method), and some
laboratory hardware (e.g. steel sonic tips, steel milling balls) are
possible sources of metal contaminations, albeit dependent on
the preparation conditions.
The colloidal stability is also a critical parameter that must
be taken into account when running biological experiments,
since the interactions of cells with the graphene environment
could change whether in a freshly-prepared suspension or after
hours or days or months of preparation. For any particular
application, the experimentalists should run control dispersions
of graphene materials in the aqueous/liquid media of interest
and continuously monitor the evolution (sedimentation) profile
by means of microscopic and/or spectroscopic techniques.14 The
structural characteristics of graphene at the first minutes after
dispersion will certainly not be the same after a couple of hours,
neither in terms of a day or more, so it is important to perfectly
know what we have in suspension in a given moment and
translate this knowledge to the biological experiment.
Based on the above considerations, the following information
is intended to be guidelines for the development of a master
file for the biocompatibility evaluation of graphene materials.
Physicochemical parameters are considered and associated
to the most useful characterization techniques for each case.
The adoption of this kind of standardized data format, when
reporting, could help to better compare the diﬀerent graphene
materials in order to clearly identify relationships between
structures and properties, favoring the development of predictive
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models and expanding our knowledge about relation between
bio- and nanoworld, clearing the way for clinical trials.
 Material name: accepted nomenclature (GO, rGO, FLG,
graphene quantum dots, etc.)7
 Physicochemical characterization (performed for the as
synthesized graphene and in biological conditions; for example
size distribution should be performed in cell culture media or
in biological buﬀers).
3 C/O ratio (techniques: XPS, elemental analysis)
3 Surface modification/functionalization related to surface
crystallinity. Possible reactivity during storage and/or under
biological conditions (techniques: XPS, elemental analysis,
Raman, TGA, dynamic light scattering, zeta potential)
3 Metal traces (techniques: X-ray electron diﬀraction, total
reflection X-ray fluorescence, atomic adsorption, inductively
coupled plasma-mass spectrometry)
3 Size: lateral dimensions and area distribution (techniques:
TEM, SEM, AFM)
3 Number of layers (techniques: TEM; Raman, AFM)
3 Surface area (techniques: Brunauer–Emmett–Teller analysis)
3 Surface charge in biological conditions (zeta potential must
be reported in the biological media or at the pH used for a given
analysis)
 Manufacturing information
Method of preparation, starting products, reagents, condi-
tions, knowledge of suspected impurities.
 Recommended processing methods
3 Conditions for safe storage
3 Dispersion agents (quantification and physicochemical
characterization)
3 Dispersion process (i.e. sonication time) and colloidal
stability at short and long times
3 Sterilization compatibility: demonstration that the sterili-
zation process does not change the final properties of the
graphene material
 Biocompatibility tests already performed with this mate-
rial: these tests should provide a complete description of the
method used, including interpretation and impact of their
results. All biological tests should be referred to a standard
reference of known activity in those tests.
3 Cytotoxicity, genotoxicity, biodegradation, distribution and
accumulation into organs, metabolism
Apart from a thorough characterization and a regulatory
standardization of the graphene materials, it is necessary to
remember that approval of a drug is an extremely long and
selective process. In this context, we think that most of the
attention should be paid to the synthetic and purification
protocols. Top down methods produce materials with an
intrinsic high polydispersity. Despite their successful use in
the research, low quality produced nanosheets will never be
approved as a drug. As for other 2D materials, the purification
of graphene flakes with a controlled and uniform lateral size
has not been yet achieved, so more work should be addressed
in this direction. This scenario is even more random in the case
of GO/rGO where exfoliation of graphite is mediated by oxida-
tion. We deal with a growing family of Hummers’ modified
methods that lack standardization and of course lead to the
production of a great variety of GOs. In the latter case,
the surface chemistry is not at all controllable and most of
the therapeutic eﬀect/drawbacks may heavily depend on the
amount and nature of the oxygenated species. The promising
results obtained in drug delivery using functionalized GO/rGO
platforms do not solve the problem of the intrinsic inhomo-
geneity of these materials, which without a standardization of
the synthetic procedure, can hardly reach serious clinical
consideration. Bottom up techniques, which allow the production
of high quality almost monodisperse materials, have led so far to
only limited amounts of materials. Graphene nanoribbons seem to
be a valid alternative to graphene as the material has a controllable
lateral size and surface chemistry. However, their production is still
limited to very small amounts.
The road of graphene in biomedical applications is therefore
very long and winding. There is still a lot to do before we can
use graphene in biomedicine, but the enthusiasm of the
scientific community is providing a host of very interesting
breakthroughs, which place graphene in pole position for
innovative diagnosis and therapy.
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